// App-Quantinova.ai

POS0370 (2022) : COMPARATIVE RETINOPATHY RISK OF HIGH- VS LOW-DOSE HYDROXYCHLOROQUINE AMONG 4,677 INCIDENT LONG-TERM USERS: EMULATED TARGET TRIAL ANALYSES

Researchers

Presenter

  • A. Jorge

Principal Investigators

  • R. Melles

  • M. Marmor

  • C. Conell

  • B. Zhou

  • J. Niu

  • Y. Zhang

  • H. Choi

Medical Centers

  • Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Boston, United States of America

  • Kaiser Permanente Northern California, Ophthalmology, Redwood City, United States of America

  • Stanford University, Department of Pathology, Palo Alto, United States of America

  • Kaiser Permanente Northern California, Division of Clinical Research, Oakland, United States of America

  • Baylor College of Medicine, Emergency Medicine, Houston, United States of America

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Diabetic retinopathy

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

Outcome

  • N/A

Study Design

  • Observational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Ironwood Pharmaceuticals and Horizon Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved